NHSMr Andrew Fisher — no licensed photograph is available, so the clinician plate is shown instead.

Clinician

Mr Andrew Fisher

Consultant in Severe Lung Disease and Lung Clinical Lead, ARCs Programme, NHS Blood and Transplant

NHS Blood and Transplant is based in Filton and Bradley Stoke (Filton, Bristol) — the organisation’s base, not a personal address.

Press citations

2

Topics

2

Hospital discharge / bed-blocking

Last quoted

Aug 2026

Mr Andrew Fisher: key facts

Kind of voice
Clinician
Role
Consultant in Severe Lung Disease and Lung Clinical Lead, ARCs Programme
Organisation based in
Filton and Bradley Stoke
Quoted on
Hospital discharge / bed-blocking, NHS waiting lists
Tracked press citations
2
Most recently quoted
27 Aug 2026

Who Mr Andrew Fisher is

Professor Andrew Fisher is a consultant in severe lung disease and the Lung Clinical Lead for the ARCs (Assessment and Recovery Centres) Programme at NHS Blood and Transplant, as well as Professor of Respiratory Transplant Medicine at Newcastle University. He has worked as a consultant in advanced lung disease, pulmonary hypertension and lung transplantation since 2004, and holds an honorary consultant post at The Newcastle upon Tyne Hospitals NHS Foundation Trust. He is Deputy Director of the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation, and his research focuses on optimising donor organ quality prior to transplantation and improving patient survival after lung transplant. He is a Past President of the International Society for Heart and Lung Transplantation (2016–2019) and a member of the British Transplant Society Council. He is known for leading national clinical trials in lung transplantation, including the E-CLAD UK study into treatment of chronic lung allograft dysfunction, and for his role in establishing and delivering the UK's first national ARCs pilot programme.

“It's important that robust evidence is generated that shows exactly how much impact the use of this device has on lung transplant activity and supports timely access to transplant for patients desperately waiting for a suitable organ.”

References for this biography

  1. 1.First lung transplant completed through UK's ARCs programme | Royal Papworth Hospital — Current role title (Lung Clinical Lead, ARCs Programme, NHS Blood and Transplant); press quote; ARCs programme description
  2. 2.Professor Andrew Fisher – Newcastle Hospitals NHS Foundation Trust — Consultant since 2004; clinical work with severe lung disease and pulmonary hypertension patients; Past President ISHLT 2016–2019; Co-Director NIHR BTRU
  3. 3.Professor Andrew Fisher – The UK Photopheresis Society — Full current role set: Newcastle University professorship, NIHR BTRU Deputy Director, Honorary Consultant at Newcastle Hospitals, ISHLT past presidency, British Transplant Society Council membership
  4. 4.Staff Profile – Newcastle University — Organisation address, qualifications (BMedSci, BMBS, FRCP, PhD), research interests, honorary roles, and esteem indicators including ISHLT Board and BTS roles
  5. 5.E-CLAD UK Central Research Team – Newcastle University — Chief Investigator role for E-CLAD UK study
  6. 6.University of Cambridge to establish two new Blood and Transplant Research Units — Co-founding of NIHR BTRU in Organ Donation and Transplantation with Cambridge
  7. 7.Study aims to discover improved treatment for lung transplant patients – Newcastle University Press — Role as Professor of Respiratory Transplant Medicine and Honorary Consultant; leadership of E-CLAD UK trial
  8. 8.Andrew Fisher PhD, FRCP – ISHLT Speaker Profile — Academic Director and Honorary Consultant, Institute of Transplantation, Freeman Hospital; graduation from Nottingham 1993; MRC fellowship 1996–99; GSK fellowship 2005–2010

Notable achievements

  • Lung Clinical Lead for the ARCs Programme at NHS Blood and Transplant; the first lung transplant using the ARCs pilot was completed in August 2026, described as the first national programme of its kind in the world. Source ↗
  • Past President of the International Society for Heart and Lung Transplantation, 2016–2019. Source ↗
  • Chief Investigator of the E-CLAD UK study, a UK-wide clinical trial across the UK's five lung transplant centres investigating treatment of chronic lung allograft dysfunction. Source ↗
  • Co-established (with Cambridge) the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation, focused on improving donor organ quality and increasing availability of suitable donor organs. Source ↗
  • Chief Investigator of the DEVELOP-UK trial, an NIHR Health Technology Assessment-funded study of donor ex-vivo lung perfusion in UK lung transplantation. Source ↗

What Mr Andrew Fisher has said

  • “I am delighted that the first lung transplant has been performed using donor lungs that have had their quality checked in an ARC pilot site before being sent to another transplant centre for a patient on their waiting list.”

    consultant in severe lung disease and Lung Clinical Lead for the ARCs Programme at NHS Blood and Transplant · NHS waiting lists · 27 Aug 2026 · National collaboration delivers first lung transplant through ARCs programme ↗

Where Mr Andrew Fisher has been quoted

  1. Machine that keeps lungs alive outside body could increase NHS transplantstheguardian.com · 27 Aug 2026
  2. National collaboration delivers first lung transplant through ARCs programmeroyalpapworth.nhs.uk · 27 Aug 2026

Related media coverage

Recent UK press coverage of their topics — not necessarily citing them directly.

Contact & links

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.

Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.